Maha Katabi is a General Partner at Sofinnova Investments focused on development-stage biopharmaceuticals with over two decades of experience managing public and private biotech companies through bull and bear markets. She invests across multiple therapeutic areas including oncology, immunology, CNS disorders, cardiovascular disease, rare diseases, and metabolic disorders, with a track record of backing companies from early clinical stages through public exits. Her thesis centers on identifying clinically-validated pathways and novel platform technologies in therapeutic development, with board-level involvement in portfolio companies